Q1 2026 revenues of ~$4.0 billion increased by 2% in U.S. dollars year-over-year (YoY), and decreased by 3% in local currency terms (LC). Excluding the Japan business venture (BV) results, revenues ...

Amgen heads into Q1 earnings with growth from key drugs offset by pricing pressure, patent losses, and biosimilar competition.

Also, since I have a history of dental problems, how can I get off Prolia in the future and still protect my bones? -- L.L.

I’m a 79-year-old female who’s in good health. I am 5 feet tall and weigh 95 pounds, and I’m very active. I’ve been taking Prolia for the past two to three years for osteoporosis, which has since ...

A major UK-based study has found that denosumab, a widely used osteoporosis medication, does not raise the risk of atypical femur fractures compared with bisphosphonates over four years. The result ...

A large real-world study of nearly 300,000 osteoporosis patients found no increased risk of atypical femur fractures with denosumab compared to bisphosphonates. The findings, presented at the 2026 ...

Adults with osteoporosis prescribed the antiresorptive denosumab were no more likely to sustain an atypical femur fracture ...

No increase in subtrochanteric or diaphyseal femur fractures was seen with denosumab use compared with bisphosphonates in 4 ...

Biocon has received a Notice of Compliance from Health Canada for Bosaya and Vevzuo, both biosimilars referencing Prolia and Xgeva, respectively.